Lucira Health Inc. (NASDAQ: LHDX) 52-Week High Located At $5.67, Forget The Dips, Just Ride The Rips


Lucira Health Inc. (NASDAQ:LHDX) does about 5.57M shares in volume on a normal day but saw 393752 shares change hands in Friday trading. The company now has a market cap of 12.24M USD. Its current market price is $0.28, marking an increase of 1.81% compared to the previous close of $0.27. The 52 week high reached by this stock is $5.67 whilst the lowest price level in 52 weeks is $0.11. The script in recent trading has seen the stock touch a high of $0.28 and a low of $0.256.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Lucira Health Inc. (LHDX) has a 20-day trading average at $0.3197 and the current price is -95.14% off the 52-week high compared with 155.19% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.2893 and its 200-day simple moving average is $1.3834. If we look at the stock’s price movements over the week, volatility stands at 13.04%, which increases to 16.83% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 44.53 to suggest the stock is neutral.

2 analysts observing the Lucira Health Inc. (LHDX) stock have set the 12-month price targets for the company’s shares at between $0.50 and $0.50. The median price target is 44.0% away from the current levels at $0.50.

FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 0 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Underweight and Wall Street’s advice is for investors to Hold the stock.

BofA Securities also downgraded the stock to “Underperform” from Neutral on April 13, 2021 at a price target of $9.

The current price level is -14.52%, -5.08%, and -80.28% away from its SMA20, SMA50, and SMA200 respectively, with the LHDX price moving above the 50-day SMA on February 17. Lucira Health Inc. (LHDX) stock is up 2.64% over the week and 5.03% over the past month. Its price is 148.07% year-to-date and -94.11% over the past year.

The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of -$3.15 below consensus estimates by -$2.77. The company’s next earnings report is expected on 05/11/2023, with forecasts estimating quarterly EPS at -$0.4 and $0 for whole year. Expected sales for next quarter are $80 million, which analysts say will come at $185.67 million for the current fiscal year and next year at $120 million. In addition, estimates put the company’s current quarterly revenue at an average of $34.66 million.

Its 12-month price target is $0.50. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $0.50, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $0.50.

Outstanding shares total 40.22M with insiders holding 10.13% of the shares and institutional holders owning 24.20% of the company’s common stock. The company has a return on investment of -34.50% and return on equity of -89.60%. Price to book ratio is 0.18 and price to sales ratio is 0.06.

Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by AlphaCentric LifeSci Healthcare F, which added 22700.0 shares to end up with 320,200 shares worth $0.13 million.


Please enter your comment!
Please enter your name here